Cancer Genetics Laboratory, University of Otago, Dunedin, New Zealand.
J Exp Clin Cancer Res. 2011 Aug 24;30(1):78. doi: 10.1186/1756-9966-30-78.
The immune response has been proposed to be an important factor in determining patient outcome in colorectal cancer (CRC). Previous studies have concentrated on characterizing T cell populations in the primary tumour where T cells with regulatory effect (Foxp3+ Tregs) have been identified as both enhancing and diminishing anti-tumour immune responses. No previous studies have characterized the T cell response in the regional lymph nodes in CRC.
Immunohistochemistry was used to analyse CD4, CD8 or Foxp3+ T cell populations in the regional lymph nodes of patients with stage II CRC (n = 31), with (n = 13) or without (n = 18) cancer recurrence after 5 years of follow up, to determine if the priming environment for anti-tumour immunity was associated with clinical outcome.
The proportions of CD4, CD8 or Foxp3+ cells in the lymph nodes varied widely between and within patients, and there was no association between T cell populations and cancer recurrence or other clinicopathological characteristics.
These data indicate that frequency of these T cell subsets in lymph nodes may not be a useful tool for predicting patient outcome.
免疫反应被认为是决定结直肠癌(CRC)患者预后的重要因素。先前的研究集中在对原发肿瘤中的 T 细胞群进行特征描述,其中具有调节作用的 T 细胞(Foxp3+Tregs)被认为既增强又减弱抗肿瘤免疫反应。以前没有研究对 CRC 区域淋巴结中的 T 细胞反应进行特征描述。
采用免疫组织化学方法分析了 31 例 II 期 CRC 患者(n=31)和 5 年随访后有(n=13)或无(n=18)癌症复发的患者的区域淋巴结中 CD4、CD8 或 Foxp3+T 细胞群,以确定抗肿瘤免疫的启动环境是否与临床结局相关。
淋巴结中 CD4、CD8 或 Foxp3+细胞的比例在患者之间和患者内部差异很大,且 T 细胞群与癌症复发或其他临床病理特征之间无相关性。
这些数据表明,淋巴结中这些 T 细胞亚群的频率可能不是预测患者预后的有用工具。